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Background: Primaquine is essential for malaria control and elimination since it is the only available drug
preventing multiple clinical attacks by relapses of Plasmodium vivax. It is also the only therapy against the sexual
stages of Plasmodium falciparum infectious to mosquitoes, and is thus useful in preventing malaria transmission.
However, the difficulties of diagnosing glucose-6-phosphate dehydrogenase deficiency (G6PDd) greatly hinder
primaquine’s widespread use, as this common genetic disorder makes patients susceptible to potentially severe
and fatal primaquine-induced haemolysis. The risk of such an outcome varies widely among G6PD gene variants.
Methods: A literature review was conducted to identify surveys of G6PD variant frequencies among representative
population groups. Informative surveys were assembled into two map series: (1) those showing the relative
proportions of the different variants among G6PDd individuals; and (2) those showing allele frequencies of G6PD
variants based on population surveys without prior G6PDd screening.
Results: Variants showed conspicuous geographic patterns. A limited repertoire of variants was tested for across
sub-Saharan Africa, which nevertheless indicated low genetic heterogeneity predominated by the G6PD A-202A
mutation, though other mutations were common in western Africa. The severe G6PD Mediterranean variant was
widespread across western Asia. Further east, a sharp shift in variants was identified, with high variant heterogeneity
in the populations of China and the Asia-Pacific where no single variant dominated.
Conclusions: G6PD variants exhibited distinctive region-specific distributions with important primaquine policy
implications. Relative homogeneity in the Americas, Africa, and western Asia contrasted sharply with the heterogeneity
of variants in China, Southeast Asia and Oceania. These findings will inform rational risk assessments for primaquine in
developing public health strategies for malaria control and elimination, and support the future development of
regionally targeted policies. The major knowledge gaps highlighted here strongly advocate for further investigation of
G6PD variant diversity and their primaquine-sensitivity phenotypes.
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The discovery of glucose-6-phosphate dehydrogenase defi-
ciency (G6PDd) occurred during the clinical development
of primaquine against the relapse of Plasmodium vivax
malaria in American prisoner volunteers during and
immediately after the Second World War [1]. The high
prevalence of this inherited disorder among people at risk* Correspondence: rosalind.howes@zoo.ox.ac.uk
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stated.of malaria [2], along with the practical difficulty of its diag-
nosis where almost all of them live [3], sharply limits the
otherwise enormous public health importance and utility
of primaquine in controlling and eliminating malaria
[4-8]. This drug is currently the only licensed therapy
active against the latent liver-stages of P. vivax responsible
for multiple relapses in the weeks, months, and several
years following a single infectious bite by an anopheline
mosquito [9]. As with the primary infection, and despite
the long-held dogma that considered vivax malaria clinic-
ally benign, each relapse carries risk of severe disease andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
Howes et al. Malaria Journal 2013, 12:418 Page 2 of 15
http://www.malariajournal.com/content/12/1/418mortality [5]. Furthermore, primaquine is the only drug
with activity against the mature transmission-stages of all
Plasmodium species [4,10,11], giving it a role of undeni-
able importance in reducing transmission levels, most par-
ticularly in preventing the spread of artemisinin-resistant
Plasmodium falciparum [12-15]. The recently published
model-based geostatistical mapping study showed that
G6PDd is prevalent across malaria-endemic countries,
with an estimated median allele frequency in these regions
of 8.0% (50% CI: 7.4-8.8) [2], thought to be driven by a
selective advantage against life-threatening malaria [16-18].
Despite its prevalence and hindrance to malaria control,
the spatial patterns of the genetically and clinically diverse
G6PD mutations are poorly documented globally; this
knowledge gap, highlighted by others [19], constitutes the
focus of the present study. A better understanding of the
spatial epidemiology of G6PD gene variants would support
assessments towards safe delivery strategies to increase
access to primaquine.
G6PD enzyme generates nicotinamide adenine dinuc-
leotide phosphate (NADPH), which represents the pri-
mary defence against oxidative stresses in red blood cells
(RBC). Mutations in the G6PD gene can destabilize the
enzyme and reduce its activity levels, leaving cells
vulnerable to damage from exogenous triggers, including
certain foods, infections, and a range of drugs, that may
lead to RBC lysis and acute haemolytic anaemia (AHA)
[20,21]. The clinical burden of G6PDd was evaluated in
the Global Burden of Disease Study 2010 [22,23], and
includes a range of pathologies, notably neonatal jaundice
and AHA. The clinical symptoms due to primaquine-
induced haemolysis range from negligible to lethal [24,25]
depending largely upon the variants involved and drug
dosing.
At least 186 mutations have been characterized in the
G6PD gene [26], although not all are polymorphic and
of clinical significance. G6PD variants have been catego-
rized into three types (Table 1) [21,25]. About half of the
known variants appear to be sporadic mutations identi-
fied in only a handful of patients [27]. These rare vari-
ants, classified as Type 1, usually express very severe
chronic disease – a pathology known as chronic non-
spherocytic haemolytic anaemia (CNSHA) – which can
result in lifelong dependency on blood transfusion [25].Table 1 G6PDd variant types
Type Residual enzyme activity Population-level prevalence
Type 1 <10% Sporadic (never polymorphic)
Type 2§ <1-50% Polymorphic
Type 3 Normal (>50%) Polymorphic (wild-type)
§Type 2 variants have previously been separated into Class II and Class III variants o
however, this subdivision is blurred and poorly defined [25].Although numerous by type, these variants never reach
polymorphic frequencies (prevalence ≥1%) and are thus
not of serious public health concern. Type 2 variants, in
contrast, do reach frequencies ≥1% and put individuals
at significant risk of haemolytic crises. These Type 2
variants correspond to the Class II and III variants of
the WHO-endorsed classification system [28,29]. Given
their public health significance, being both polymorphic
and clinically significant, Type 2 variants are the focus of
the present study. Type 3 variants express phenotypically
normal G6PD activity and present no clinical or public
health concerns.
The G6PD A- variant from Africa has been the most
thoroughly studied with respect to sensitivity to prima-
quine. This may be a consequence of being the first
studied and the most accessible (in African American
volunteers) during primaquine development [30]. This
variant typically exhibits residual enzyme activity of
about 5-10% of normal levels [31]. Primaquine toxicity
in the G6PD A- volunteers was relatively mild and self-
limiting [32]; G6PD A- individuals dosed with daily
primaquine for four months have been observed to
typically recover from relatively shallow AHA within
about three weeks, despite continued daily dosing [33].
In contrast, the G6PD Mediterranean variant, which is
common across southern Italy (particularly Sardinia)
and the Arabian Peninsula [34], exhibits exceedingly low
residual enzyme activity (<1% [35]) and predisposes
individuals to favism [36,37] and clinically severe AHA
following primaquine therapy [12,35,38,39]. G6PD Mahi-
dol is the best-characterized Asian variant and is con-
sidered predominant across Myanmar and Thailand
[40,41]. Enzyme activity in G6PD Mahidol individuals is
reduced to 5-32% of normal levels [42], and its prima-
quine sensitivity phenotype lies between that of the
G6PD A- and Mediterranean variants [43,44]. As for the
balance of many dozens of other G6PD variants, residual
enzyme activity is generally known for many [26], but
the primaquine sensitivity phenotypes for any of these
remains effectively unknown [4]. There may be an in-
verse correlation between residual enzyme activity and
AHA sensitivity to primaquine (as roughly seen with the
three variants discussed), but this is not yet firmly
established.Clinical significance Primaquine-associated public
health concern
Severe and chronic: CNSHA None – too rare
Asymptomatic until exposed to
an exogenous trigger
Yes – commonly inherited and cause
individuals to be at risk of haemolysis
None None – G6PD normal
f the WHO-endorsed G6PDd variant classification [28,29]. For many variants,
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and our limited knowledge thereof, greatly compounds
the difficulty of addressing the technical and practical
limitations which this deficiency imposes on primaquine
treatment for attacking the endemic malarias [45].
National authorities responsible for the prevention, con-
trol and treatment of endemic malaria naturally strive for
evidence-based practices that minimize risk and maximize
benefit. The complexity of the problem imposed by
G6PDd – both by its genetic variability and its heteroge-
neous prevalence [2] – compounds the difficulty of devel-
oping practical and useful tools for assessing risk and
benefit. The present study begins the task of characteriz-
ing G6PD variant spatial distribution and diversity, with
the aim of contributing towards the evidence-based pol-
icies for primaquine treatment so essential to realizing the
vision of malaria elimination.
Methods
The aim of this study was to map population surveys
reporting the prevalence of the G6PD variants of greatest
public health significance. A systematic literature review
was conducted of online biomedical databases for all
records referring to “G6PD” or “glucose-6-phosphate
dehydrogenase” and then cross-referenced with previously
published G6PD variant databases [26,46-50]. The study
was limited to data from malaria-endemic countries
[2,51,52], corresponding to where primaquine therapy is
needed. Refer to Additional file 1 for more detailed
descriptions of the methodology. The assembled datasets
are available from the authors on request.
Survey inclusion criteria
The assembled library of sources was reviewed for popu-
lation surveys of G6PD variants and those meeting a
specific set of inclusion criteria (Figure 1) were identi-
fied. First, only surveys that could be geopositioned to at
least the national level were included, and these were
mapped to the highest spatial resolution available, ideally
as point locations (e g, villages). Second, to ensure that
survey samples were widely representative of the com-
munities being studied, only surveys which provided
apparently unbiased prevalence estimates were inclu-
ded: all case studies and patient groups, malaria patients
(to avoid underestimating frequencies of G6PD variants
which may provide a protective effect against malaria),
family studies, and samples selected according to ethnic
background were therefore excluded. Third, only surveys
using molecular diagnostics were included to avoid the
diagnostic uncertainty of surveys reliant on biochemical
methods (see Additional file 1).
Surveys meeting these criteria were of two types
depending upon the nature of the population samples
surveyed and were mapped as two separate series:Map series 1: variant proportion maps
Studies examining individuals who had been previously
identified as phenotypically G6PDd from a population
screening survey and were being followed-up for mole-
cular diagnosis of underlying mutations were included in
map series 1. Pie charts were chosen to display the
relative proportions of the different variants identified in
each of the surveys, with each colour-coded segment
proportional to the variant’s relative frequency across
the study sample. Sample size was reflected in the rela-
tive sizes of the pie charts, which was transformed on a
square-root scale to allow clear visualization.
It is important to note that studies did not always at-
tempt to identify all the variants represented in the legends
of the maps. For instance, if only G6PD Mediterranean
was tested for among a sample of deficient individuals,
those individuals who tested negative would be included in
the “Other” category, regardless of whether they expressed
one of the other variants listed in the legend or a com-
pletely different one. The absence of a specific variant from
a sample can only be inferred if no “Other” samples are
reported.
Map series 2: allele frequency maps
Surveys which investigated G6PD variants in cross-
sectional population samples without prior phenotype
screening were included in map series 2. These studies
estimated the allele frequencies of selected G6PD vari-
ants at the population level and were mapped spatially
using bar charts to represent the allele frequencies. This
visualization conveyed the important concept that fre-
quency estimates are only available for variants that were
included in the diagnoses, underlining the importance of
knowing which variants had been tested for. The vari-
ants tested for were named in the vertical bars of the bar
charts. Empty spaces along the x -axis indicate that the
named variant was tested for but not identified in the
population sample. The size of the plots meant that in
some cases, significant spatial uncertainty was introduced
to their positioning on the map (Additional file 1).
The G6PD gene’s X-linked inheritance means that allele
frequencies correspond to frequencies among males. Het-
erozygous inheritance in females makes allele frequency
estimates from female samples harder to calculate confi-
dently as not all studies consistently distinguished hete-
rozygotes from homozygotes. For reliability, therefore,
only data from males were included in these variant allele
frequency maps.
Variant inclusion criteria
Given the diversity of G6PD variants, for the purposes of
this mapping study it was necessary to identify those
variants that presented a primary public health concern.
This study focussed on Type 2 variants which (i) express
Figure 1 Survey inclusion criteria and G6PDd variant map outputs. Orange rectangles indicate the exclusion criteria, grey hexagons
summarize the two final input data, and green rods represent the two map types.
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clinically significant by predisposing individuals to
haemolytic anaemia; and, (iii) reach polymorphic allele
frequencies at the population level (Table 1). Although
77 Type 2 variants have so far been described [26], the
database of population survey data compiled in this
study indicated that most variants were reported fewer
than ten times (most fewer than three) and, when identi-
fied, were found to have low prevalence. A clear subset
of variants was responsible for the majority of investi-
gated G6PDd cases (Additional file 1); these were defi-
ned for the purposes of this study to be those variants
reported from a minimum of ten localities across the
malaria-endemic region. This ensured that the spatial
distributions of the most significant variants could be
legibly visualized in the maps. Fifteen variants met these
criteria: G6PD A-, Canton, Chatham, Chinese-5, Coimbra,Gaohe, Kaiping, Kalyan-Kerala, Mahidol, Mediterranean,
Orissa, Quing Yan, Union, Vanua Lava, and Viangchan
(Figure 1).
Results
The database
A total of 18,939 bibliographic sources were identified
from keyword searches, of which 2,176 were considered
likely to include spatial information about G6PD vari-
ants. Following their detailed review, 93 published and
unpublished sources were identified which reported
surveys eligible for inclusion in the maps (listed in the
Additional file 2). From these sources (which could each
report several surveys from multiple locations), 138
population surveys could be geolocated and met the
criteria for map series 1, as these were of community sam-
ples which had undergone prior screening for phenotypic
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population surveys of community samples providing
variant frequency estimates. Map series 1 data were pre-
dominantly from populations in Asia (123/138 surveys;
89%), while map series 2 data were almost exclusively
from the Africa + region (Africa, Yemen and Saudi Arabia
[53]: 20/24 surveys, or 83%). These database descriptors
are summarized in Table 2.
Distribution of G6PD variants in malaria-endemic regions
The maps reveal conspicuous distinct geographical
patterns in the distribution and prevalence of G6PD
variants across regions. The two series of maps represent
both the relative proportions of the variants responsible
for phenotypic G6PD enzyme deficiency (Figures 2, 3, 4,
5, 6, 7) and the allele frequencies of selected variants
(Figure 8 and Additional files 3, 4 and 5). Together, these
maps revealed a number of clear patterns further
described below: (i) a relatively low diversity of G6PD
variants reported from populations of the Americas and
Africa + regions, among whom variants of the G6PD A-
phenotype are predominantly searched for and reported;
similarly, G6PD Mediterranean was predominant in west
Asia (from Saudi Arabia and Turkey to India); (ii) a
sharp shift in variants identified east of India, showing
no admixture with the common variants of west Asia;
(iii) high variant diversity in east Asia and the Asia-
Pacific region, with multiple variants co-occurring and
no single variant being predominant.
G6PD variants in the Americas
Relatively few surveys were available from the Americas
(nine in map series 1, one in map series 2). Figure 2A
indicates that among G6PDd individuals, the predomin-
ant variant was G6PD A- (in the majority of cases
encoded by the G6PD A-202A mutation, though the
G6PD A-968C variant was common in some samples),
identified in 91% of deficient individuals surveyed across
the region (579 of 636 total G6PDd individualsTable 2 Summary of input data according to map type
Africa+ Americas Asia Global
(Malaria-endemic countries only)
Map series 1 Variant
proportion maps
Nsurveys 6 9 123 138
Ncountries 5 4 16 25
NG6PDd indivs 258 636 5,278 6,172
Mean
sample size
43 71 43 45
Map series 2 Variant
frequency maps
Nsurveys 20 1 3 24
Ncountries 13 1 2 16
Nmale indivs 6,796 509 448 7,753
Mean
sample size
340 509 149 323surveyed). Other variants identified included G6PD Med-
iterranean563T and Seattle844C (the latter was classified as
part of the “Other” category as it was only reported twice,
both instances from Brazil where it reached a prevalence
of 13% (n = 2/15, [Additional file 2: S63] and 5% (n = 9/
196, [S30])). A survey of Mexicans reported 61% of defi-
cient cases being due to various G6PD A- variants, but did
not test for any other variant (e g, G6PD Mediterranean),
explaining the large proportion of “Other” variants
[Additional file 2: S85].
A single community screening survey could be identi-
fied which investigated G6PD variant allele frequencies.
This was in Acrelândia, Brazil, and searched for only one
single-nucleotide polymorphism (SNP): G6PD A-202A. An
allele frequency of 6% (n = 509, [Additional file 2: S14])
was reported (see Additional file 3).
G6PD variants in Africa, Yemen and Saudi Arabia (Africa+)
Very few studies (n = 6) investigating the variants of
known G6PDd individuals were identified from the
Africa + region (Figure 3). Where available, both in West
Africa and the western Indian Ocean islands, surveys
indicated G6PD A-202A to be the predominant variant; in
Saudi Arabia, the G6PD Mediterranean variant was
responsible for 78% of G6PDd cases in two surveys in the
western coastal city of Jeddah [Additional file 2: S6,S28].
Surveys investigating population-level frequencies of
specific G6PD variants were more common (Figure 8
and Additional file 4). These consistently looked for
SNPs of G6PD A-, notably focussed on the G6PD A-202
locus. Frequencies of this SNP were over 20% in surveys
from Nigeria and Côte d’Ivoire in West Africa, and
found at 19% in coastal Kenyan populations. The G6PD
A-968C mutation encodes a similar phenotype to G6PD
A-202A and was found to be the more common of the
two in West African populations (in The Gambia and
Senegal, for instance [Additional file 2: S21,S25]); despite
this, only six of 20 surveys across Africa + included the
G6PD A-968 SNP in their diagnoses. Large population
surveys in East Africa (n = 311 in Uganda [Additional file
2: S38] and n = 2,756 in Kenya [Additional file 2: S76])
found no evidence of the G6PD A-968C mutation despite
frequencies of 12 and 19% of the G6PD A-202A mutation,
respectively.
Most population surveys (70%) in the Africa + region
tested the G6PD A-376 locus. Although this mutation has
barely any clinical effect, it is commonly co-inherited
with mutations at other loci, together encoding the
range of G6PD A- variants (Figure 8). The G6PD A-376G
variant had very high prevalence among sub-Saharan
African populations, and in all cases affected over 10%
of individuals surveyed; further, in a subset of ten out of
16 of these surveys, its frequency reached 25-50%.
Exceptions to this high G6PD A-376G prevalence were
Figure 2 G6PDd variant proportion map: Americas (map series 1). Map includes nine surveys with a mean sample size of 71 (range: 8-196);
one survey was mapped at the national level. Pie charts represent individuals previously identified as G6PDd. Sample size is reflected in the size
of the pie charts, which is transformed for clarity on a square-root scale. Surveys which could only be mapped to the country-level are indicated
by a white star; this applied to seven surveys globally. Spatial duplicates from independent studies were mapped with a “jitter” of 0.5-1 decimal
degrees in their latitude or longitude coordinates to allow visualization of the multiple charts. Malaria-endemic countries in the region mapped
are shown with a yellow background; white backgrounds indicate endemic countries outside the region in focus; grey backgrounds represent
malaria-free countries. G6PDd variants that could not be diagnosed were reported as “Other”.
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reported low (<5%) prevalence [Additional file 2: S41];
the G6PD A-202A mutation was not detected in these
samples.
G6PD variants in Asia and Asia-Pacific
Greatest G6PD variant diversity globally was across the
Asia and Asia-Pacific regions (Figures 4, 5, 6, 7) where
up to ten variants were reported to co-occur within
single populations. Furthermore, significant proportions
of “Other” cases were frequently reported in the variant
proportion maps (map series 1), indicating that genetic
diversity is greater than represented by the pie charts in
these maps.
From Turkey to Pakistan (Figure 5), G6PD Mediterranean
was predominant, identified in 728 of 895 G6PDd indivi-duals examined (81%). Two variants, G6PD Kalyan-
Kerala949A and Orissa131G, were reported exclusively from
Indian populations. On the Indian sub-continent, these
two variants and the G6PD Mediterranean variant repre-
sented the majority (88% of n = 555 G6PDd individuals
tested) of deficiency cases, though notable proportions
(up to 80%) of “Other” cases were also reported from
eastern and southern India.
East of India, a completely different set of variants
emerged (Figure 6). G6PD Mahidol487A predominated
across Myanmar, with 98 of 117 G6PDd individuals
(84%) diagnosed across 14 locations as carrying this
variant. Variants common among G6PDd individuals in
southeast China were largely unique to these popula-
tions. Of the 2,883 G6PDd cases from China, the com-
monly diagnosed variants included G6PD Kaiping1388A
Figure 3 G6PDd variant proportion map: Africa+ (map series 1). Map includes six surveys with a mean sample size of 43 (range: 5-110). One
survey was mapped at the national level. (See Figure 2 for full legend).
Figure 4 G6PDd variant proportion map: Asia (map series 1). Map includes 87 surveys with a mean sample size of 53 (range: 1-532). Four
surveys were mapped to the national level. (See Figure 2 for full legend).
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Figure 5 G6PDd variant proportion map: West Asia (map series 1). A higher resolution map of Figure 4.
Figure 6 G6PDd variant proportion map: East Asia (map series 1). A higher resolution map of Figure 4.
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Figure 7 G6PDd variant proportion map: Asia-Pacific (map series 1). Panel A show the full map, which includes 36 surveys with a mean
sample size of 18 (range: 1-128). One survey was mapped at the national level. The East Nusa Tenggara province islands identified by the dotted
box are shown at higher resolution in Panel B. (See Figure 2 for full legend).
Figure 8 G6PD A- variant SNP frequency map for Africa (map series 2). Bar charts representing the frequencies of G6PD variants. The
variants that were tested for in each location are listed above the x-axis. Empty spaces along the x-axis indicate that the named variant was
tested for but not identified in the population sample. Survey locations are mapped to closest approximation at the point of origin of the plots
and exact locations shown in Additional file 4. Sample size is listed under each plot. Equivalent maps of the Americas and Asia are Additional files
3 and 5.
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(792 cases; 27%), Gaohe95G (265 cases; 9%), Chinese-51024T
(104 cases; 4%) and Quing Yan392T (87 cases; 3%). The dis-
tribution of G6PD Viangchan871A was diffuse, reportedly
common from Laos (where examination of 15 G6PDd in-
dividuals all carried this variant [Additional file 2: S34])
and Cambodia (reported from 61 out of 64 G6PDd indi-
viduals [Additional file 2: S43]) to Papua New Guinea
(where a sample of 13 G6PDd individuals included nine
with this variant [Additional file 2: S33]).
Variants across the Asia-Pacific region were also highly
heterogeneous (Figure 7). The common pattern emer-
ging from the 36 surveys of deficient individuals identi-
fied from this region (nindivs = 635) was the diversity of
variants and the heterogeneity of their prevalence among
different populations. Furthermore, it should be noted
that 20 of these surveys tested fewer than ten G6PDd
individuals, limiting the diversity that would be captured
and thus the representativeness of these reports. The
greatest diversity identified in a single survey was from
the Malaysian neonatal screening programme in Kuala
Lumpur, which recorded ten variants from an investiga-
tion of 86 G6PDd newborns [Additional file 2: S4]. The
short spatial-scale heterogeneity of this co-occurring vari-
ant diversity is illustrated by a set of surveys across the
East Nusa Tenggara province of Indonesia (Figure 7B).
Amid this co-occurring variant heterogeneity, the G6PD
Vanua Lava383C variant was the most common variant
reported from Indonesian studies (identified in 84 out of
249 G6PDd individuals tested).
Only three allele frequency surveys (map series 2)
could be identified from the Asia region (of 24 globally)
[Additional file 2: S66,S83]. G6PD Mahidol was most
commonly tested for, with allele frequencies of 12% and
18% (ntested = 353 and 11, respectively; Additional file 5).
Two surveys in Thailand tested for a broader range of
variants; one found five variants (G6PD Canton, Kaiping,
Mahidol, Union and Viangchan; ntested = 84) at allele fre-
quencies of 1-2%; and the other, with a smaller sample
size (ntested = 11), identified only the G6PD Mahidol
variant [Additional file 2: S66].
Discussion
Over a third of the world’s population lives at risk of P.
vivax infection [14,52,54]. Limited evidence underpins
estimates of clinical cases, but these have been estimated
at 70-400 million annually [55,56], including potentially
severe illness and death [5,24,57,58]. In the context of
malaria elimination, therapy must target all infections,
including asymptomatic and submicroscopic blood-stage
infections, dormant liver-stage hypnozoites as well as
clinical cases [59,60]. One of the many consequences of
a half-century of neglect of P. vivax has been the failure
to address the primaquine toxicity problem with G6PDdand thereby solve the real problem of lack of access to
primaquine for almost all malaria patients. No non-toxic
therapeutic alternatives exist, and existing G6PDd diag-
nostics are largely impractical in point-of-care settings
[4,6,21,45,56].
Fear of harm also leads to avoidance of primaquine as
a P. falciparum transmission-blocking agent. The single
transmission-blocking 0.75 mg/kg dose, consistently
inconsequential in G6PD A- volunteers, reliably caused
20-30% drops in haematocrit in healthy Europeans with
G6PD Mediterranean [39]. This risk, acknowledged at
least 30 years ago, was only acted upon in 2012 with the
WHO offering a recommendation for a lower dose of
primaquine (0.25 mg/kg) gametocytocide alongside P. fal-
ciparum blood schizontocidal treatment with no require-
ment for prior G6PDd testing [10,11,61-63]. Nonetheless,
many nations, in particular in Africa where there has been
an almost complete lack of experience with primaquine
[61] and where G6PDd prevalence is commonly greater
than 10% [2], still resist use of this drug. An understanding
of the therapeutic risks from primaquine in relation to the
G6PD variants predominant in each region will contribute
to the body of evidence on which to base policy.
Access to safe therapy either requires an alternative
non-haemolytic drug or a practical means to identify
G6PDd P. vivax malaria patients in remote, impoverished
sites. Neither is likely in the short-term and improved use
of primaquine promises immediately applicable and useful
prospects [21]. This aim demands refined knowledge of
the spatial epidemiology and primaquine-sensitivity phe-
notypes of G6PD variants. Development of primaquine
treatment strategy could exploit, for example, the total
dose effect (whereby therapeutic efficacy is dependent
upon the total drug dose irrespective of the regimen dur-
ation [64-66]), to tailor population/region-specific dosing
parameterized according to the highest dose safely toler-
ated by individuals with the most vulnerable local G6PD
variant.
G6PD variants in Africa
The G6PDd phenotype has long been considered homo-
genous across African populations, with much of the
pre-molecular era literature reporting G6PD A- from
electrophoresis assays across the continent [34]. The
early investigations of “primaquine sensitivity” among
G6PD A- volunteers found primaquine-induced haemoly-
sis to be mild and self-limiting [1,30,64,67-69]. Neverthe-
less, the haemolytic susceptibility of this “mild” variant has
been observed through severe reactions requiring transfu-
sion [70], as well as through the failure of the Lapdap
(chlorproguanil-dapsone) anti-malarial trials [71,72], and
as haemolysis induced by the ingestion of fava beans [73],
a pathology previously thought to only be triggered by
more severe variants [74]. Haemolysis associated with
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variants in some circumstances or settings, ought not be
universally characterized as “mild” as this risks leading to
misplaced confidence in a relatively cavalier application of
the drug.
Molecular analyses of G6PD variants among Africans
revealed a diversity of SNPs within the umbrella of the
G6PD A- phenotype [75]. The data, here mapped spatially,
indicated a transition of SNP predominance from west
(G6PD A-968C polymorphism) to east (G6PD A-202A wide-
spread and G6PD A-968C apparently absent). However,
expansion of the relatively small number of surveys (n = 20)
may reveal more complex distributions. Furthermore, the
true diversity of G6PD variants cannot be discerned from
the assembled surveys; it is not possible to know what
proportion of genetic diversity is reflected in the map
(Figure 3) because the diagnoses are limited to assessing
the presence or absence of a limited number of anticipated
SNPs, without any prior identification of phenotypically
deficient hosts (as in map series 1). Full gene sequencing
is the only reliable way of identifying all gene variants in
the population. Genetic diversity within the umbrella
G6PD A- phenotype may explain the spectrum of expres-
sion levels observed [70]: inheritance of a single SNP may
not be sufficient to explain the observed phenotype. If
these patterns of co-occurring SNP diversity encoding
variable G6PD A- phenotypes are widely observed, a
haplotype-based approach which allows for the co-
inheritance of multiple SNPs may be required if the use of
molecular diagnostics is to the scaled-up, as seems to be
increasingly common [75]. Despite its obvious limitations
to field-based applications, a gene-wide haplotype per-
spective would also allow increased compatibility with the
rapidly expanding human genome sequencing efforts
which are cataloguing human genetic diversity [76,77].
Although demand for primaquine has historically been
low across Africa [78], it was Ethiopia that reported the
highest number of P. vivax cases globally in 2011 (665,813
cases; [79]). G6PDd prevalence has been estimated at 1.0%
in Ethiopia (50% CI: 0.7-1.5) [2], though no molecular
information exists to indicate which variants may be
responsible. Furthermore, beyond these areas with ac-
knowledged endemic P. vivax, the status of transmission
in human populations previously considered refractory to
infection [78] is being brought into question by several
lines of evidence [80-86]. The use of primaquine for P. fal-
ciparum control may also increase following the new
WHO gametocytocide guidelines [63]. The elimination
agenda includes African nations, with most located at the
fringes of entrenched holo-endemic transmission [87,88],
and the pressure to apply primaquine both as a hypnozoi-
tocide for P. vivax and Plasmodium ovale, and as a game-
tocytocide for P. falciparum will increase with further
progress towards zero transmission. A more detailed andtargeted understanding of African G6PD epidemiology is
necessary beyond the opportunistic surveys presented in
this paper.
G6PD variants in West Asia
The G6PD Mediterranean variant, appearing predominant
across southwest Asia and exceedingly common in much
of India (especially western regions), is known to be highly
sensitive to AHA induced by primaquine. This wide distri-
bution and dominance of G6PD Mediterranean presents a
significant hurdle to the malaria elimination programmes
in West Asia, which include Azerbaijan, Georgia, Iran,
Iraq, Kyrgyzstan, Saudi Arabia, Tajikistan, Turkey, and
Uzbekistan [89]. These nations must consider the rela-
tively high risk of serious harm caused by unintentional
dosing of G6PDd patients in need of malaria therapy. Im-
plementation of G6PDd screening prior to primaquine
radical cure therapy would greatly mitigate such risks and
accelerate progress to malaria elimination in this region.
Although G6PD Mediterranean was common across
Indian populations, two other variants were also fre-
quently reported which were indigenous to populations
from this subcontinent: G6PD Kalyan-Kerala and
Orissa. Little is known of the primaquine sensitivity
phenotypes of these two variants. Since almost half of
the global population at risk of P. vivax malaria occurs
in this single nation [52,79,90] studies characterizing
such sensitivity would ultimately prove very useful in
planning towards elimination.
G6PD in East Asia and the West Pacific
The maps of eastern Asia and the western Pacific
present the most complex picture of G6PD variants
globally, coinciding with regions of heterogeneous and
high P. vivax endemicity [52]. Almost all the common
variants of public health concern globally were reported
from this region. Reasons for this genetic diversity are
unclear, but it is interesting that P. falciparum parasites
(postulated to be selective agents of G6PDd [16]) have
been found to show a greater degree of population struc-
ture with lower genetic relatedness between populations
in Asia than across Africa [91]. As well as this overall
diversity, the structure of G6PD variant heterogeneity
with multiple variants co-occurring is starkly different
from other areas where single variants predominate.
Despite large variant diversity across this region where
many countries now target elimination (thus require
primaquine therapy) [89], only one truly Asian variant
has been examined in relation to AHA sensitivity to
primaquine. G6PD Mahidol, common across Myanmar
and parts of Thailand (Figure 6), exhibits residual G6PD
enzyme activity ranging between 5-32% [42]. A handful
of small primaquine sensitivity studies examining this
variant have been conducted in Thailand, reporting very
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weekly primaquine regimens [40,92,93], as well as to
single-dose regimens of P. falciparum transmission
blocking therapy [94]. However, the G6PD Mahidol
primaquine sensitivity phenotype must not be assumed
to be representative of the region. As emphasized by the
WHO Expert Review Group on primaquine in 2012
[62,63], far greater evidence-based understanding of these
phenotypes among the many common Asian variants is
urgently needed. The identity and distribution of variants
as sensitive as G6PD Mediterranean in the Asia-Pacific
region remains unexplored and unknown. This lack of
understanding threatens patients and programmes with a
more aggressive roll-out of primaquine therapy. In popu-
lations of such high heterogeneity, a dual approach of
phenotypic screening followed by variant analysis of
residual enzyme activity may be required to identify
such risks.
The danger of under-diagnosing deficiency by using
molecular identification alone (i e, the data informing
map series 2) is illustrated by comparison of the two
types of maps (Figure 2C and Additional file 5). If only a
selected subset of perceived “common” variants are used
in population screening surveys, a proportion of deficient
individuals may be missed and put at risk from prima-
quine therapy: only those variants that are looked for can
be identified. The maps presented here also repeatedly
highlight considerable proportions of “Other” G6PD vari-
ants. These correspond to an unknown haemolytic risk,
and hint towards an ever greater diversity of variants.
Only full gene sequencing will allow full characterization
of the diversity in this polymorphic gene.
Conclusions
Both the failure to treat P. vivax infections and the treat-
ment itself carry some risk of severe clinical complications
[5,24,62] (Recht J, Ashley EA, White NJ:8-aminoquino-
lines safety review for WHO primaquine ERG, unpub-
lished). Each repeated episode of acute P. vivax malaria
carries possibilities of delayed or improper diagnosis,
improper treatment, onward transmission, serious illness,
and death [5,24]. Likewise, primaquine-induced AHA in
G6PDd patients may provoke renal failure and require
multiple transfusions for recovery [24,43]. Improper clin-
ical management of primaquine-induced haemolysis may
lead to death [24], although the relative risks of this
remain poorly documented and are likely to be rare.
Similarly, scaled-up application of low-dose transmission-
blocking primaquine against P. falciparum will likely
emerge as a key strategy towards elimination, especially in
the context of artemisinin-resistant P. falciparum malaria.
Evidence-based assessment of the risks incurred with
primaquine therapy in any given region is essential for the
development of rational strategies to minimize harmcaused by either the parasite or the drug used to attack it.
The maps presented in this article offer a first glimpse at
the distribution of variants of public health significance
across malaria-endemic regions. Their implications are
discussed with respect to the regionally specific issues
associated with the ramping up of primaquine therapy on
the strategic road to elimination.
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